Flec-SL

Symptomatic bradycardia or symptomatic sick sinus syndrome unless treated with a permanent pacemaker

Symptomatic higher degree AV nodal block (grade II or III) unless treated with a permanent pacemaker

Brugada syndrome

Typical angina pectoris symptoms at rest or during exercise

Known untreated coronary artery disease with high-degree coronary stenosis (> 80% reduction in luminal diameter)

Myocardial infarction within the last 3 months

Left ventricular ejection fraction of more than 40%

Creatinine clearance < 50 ml/min*1.73 m2 as determined by the Cockroft-Gould formula. The digital data management system will calculate this value for you during the inclusion process. For completeness of documentation, the formula is given below:

Men: Creatinine clearance (ml/min) = (140 – age(years)) * body weight (kg) / (72 * serum creatinine level (mg/dl))

Women: Value for men * 0,85

Manifest hepatic insufficiency

Hyperthyroidism or hypothyroidism manifested clinically and in laboratory tests (TSH, T3, T4)

Females who are pregnant or breast feeding

Females of childbearing potential who are not using a scientifically accepted method of contraception

Participation in a clinical trial within the last 30 days. Simultaneous participation in a registry (e.g. project AB1 of the AFNET) is permitted.

Drug addiction or chronic alcohol abuse

Legal incapacity, or other circumstances which would prevent the patient from understanding the aim, nature or extent of the clinical trial

Evidence of an uncooperative attitude

Prolongation of the QRS complex by more than 25% during flecainide treatment (measured as the difference in QRS duration between the baseline ECG and the ECG at cardioversion (34))